DC 欄位 | 值 | 語言 |
dc.contributor | 臺大公衛學院-流行病學與預防醫學研究所;臺大醫學院-一般醫學科;臺大醫學院-內科;臺大醫學院-法醫學科暨研究所;臺大醫學院-病理學科暨研究所; | en |
dc.contributor.author | Lee, Yi-Chia | en |
dc.contributor.author | Chen, Tony Hsiu-Hsi | en |
dc.contributor.author | Chiu, Han-Mo | en |
dc.contributor.author | Shun, Chia-Tung | en |
dc.contributor.author | Chiang, Hung | en |
dc.contributor.author | Liu, Tzeng-Ying | en |
dc.contributor.author | Wu, Ming-Shiang | en |
dc.contributor.author | Lin, Jaw-Town | en |
dc.creator | Lee, Yi-Chia;Chen, Tony Hsiu-Hsi;Chiu, Han-Mo;Shun, Chia-Tung;Chiang, Hung;Liu, Tzeng-Ying;Wu, Ming-Shiang;Lin, Jaw-Town | en |
dc.creator | 林肇堂 ;陳秀熙 ;李宜家 ;邱瀚模 ;孫家棟 ;吳明賢 | zh-tw |
dc.date | 2013 | en |
dc.date.accessioned | 2014-02-14T09:45:37Z | - |
dc.date.accessioned | 2018-07-11T07:08:12Z | - |
dc.date.available | 2014-02-14T09:45:37Z | - |
dc.date.available | 2018-07-11T07:08:12Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/259833 | - |
dc.description.abstract | Objective To evaluate the benefit of mass eradication of Helicobacter pylori infection in reducing premalignant gastric lesions.
Design Mass eradication of H pylori infection was started from 2004 for a Taiwanese population with prevalent H pylori infection, who were >30 years of age. Participants positive for the C-13-urea breath test underwent endoscopic screening and 1-week clarithromycin-based triple therapy. For subjects whose initial treatment failed, 10-day levofloxacin-based triple therapy was administered. The main outcome measures were changes in the prevalence of H pylori infection and premalignant gastric lesions, and changes in the incidence of premalignant gastric lesions and gastric cancer before (1995-2003) and after (2004-2008) chemoprevention using various comparators.
Results The reduction in H pylori infection was 78.7% (95% CI 76.8% to 80.7%), and the estimated incidence of re-infection/recrudescence was 1% (95% CI 0.6% to 1.4%) per person-year. The effectiveness of reducing the incidence of gastric atrophy resulting from chemoprevention was significant at 77.2% (95% CI 72.3% to 81.2%), while the reduction in intestinal metaplasia was not significant. Compared with the 5-year period before chemoprevention and in the absence of endoscopic screening, the effectiveness in reducing gastric cancer incidence during the chemoprevention period was 25% (rate ratio 0.753, 95% CI 0.372 to 1.524). The reduction in peptic ulcer disease was 67.4% (95% CI 52.2% to 77.8%), while the incidence of oesophagitis was 6% (95% CI 5.1% to 6.9%) after treatment.
Conclusions Population-based eradication of H pylori infection has led to a significant reduction in gastric atrophy at the expense of increased oesophagitis. The ultimate benefit in reducing gastric cancer incidence and its mortality should be validated by a further long-term follow-up. Trial registration number NCT00155389. | en |
dc.format.extent | 108 bytes | - |
dc.format.mimetype | text/html | - |
dc.language | en-us | en |
dc.relation | Gut, 62(5), 676-682 | en |
dc.relation.ispartof | Gut | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention | en |
dc.relation.pages | 676-682 | - |
dc.relation.journalvolume | 62 | - |
dc.relation.journalissue | 5 | - |
dc.identifier.uri.fulltext | http://ntur.lib.ntu.edu.tw/bitstream/246246/259833/1/index.html | - |
item.grantfulltext | open | - |
item.fulltext | with fulltext | - |
顯示於: | 醫學系
|